Pricing

Project-based pricing. Gate-ready deliverables.

Each tier is a fixed-fee engagement with ranked targets and evidence dossiers. Resistance mapping, proprietary cohort integration, and custom GNN training are quoted per scope.

Explorer

$75K

2 weeks delivery

Single indication, public multi-omics data, up to 500 genes evaluated

Multi-omics integration
Ranked target list (top 8)
Druggability + safety scores
Evidence summary per target
Email support

Start project

Frequently asked questions

How do you validate target rankings?: Across closed engagements, 75 to 90 percent of Priority A targets were supported by independent clinical or genetic evidence at portfolio review. Rankings are calibrated against gate outcomes, not public benchmarks alone.
What data formats do you accept?: GWAS summary statistics, bulk and single-cell RNA-seq (FASTQ or count matrices), proteomics tables, and structured CSV gene lists. We integrate public repositories (GEO, Open Targets) and client proprietary cohorts under NDA.
Can you reconcile with our internal target lists?: Yes. We produce reconciliation reports showing which internal hits are upgraded, downgraded, or confirmed—with documented rationale for each change.
What's included in an evidence dossier?: Each dossier covers genetic evidence, expression context, pathway role, druggability score, safety tier, competitive landscape, evidence concordance tier, and recommended validation experiments.
Do you sign IP and confidentiality agreements?: Always. We sign a mutual NDA before any technical discussion. All generated analysis and dossiers belong to the client by default.